Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis
Year: 2024
Type: article
Study design: Case Report
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder with poor clinical outcomes. Use of emapalumab, an IFN-γ inhibitor, enables primary HLH control in over 85 % of affected children. However, data on emapalumab use for Epstein-Barr virus-associated HLH (EBV-HLH) are limited. This report presents the cases of three patients with EBV-HLH, highlighting the successful integration of low-dose emapalumab in combination with chemotherapy as a novel therapeutic approach for patients diagnosed with EBV-HLH. This regimen resulted in rapid disease symptom control and hematological parameter improvement and facilitated successful stem cell transplantation. This report highlights the potential of low-dose emapalumab combined with chemotherapy as an effective bridging therapy to allogenic hematopoietic stem cell transplantation in EBV-HLH patients.
Source: Transplant Immunology
Authors: Wenjuan Zhu, Fei Zhou, Yue Song, Shiyuan Zhou, Feng Du, Qian Zhu, Ziyi Wang, Liyun Bai, Jianhong Fu, Xiao Ma, Xiaojin Wu, Xuefeng He
Institution: First Affiliated Hospital of Soochow University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,140
OpenAlex ID: W4405675932